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Abstract 
T-cell acute lymphoblastic leukemia is caused by the accumulation of multiple oncogenic 
lesions, including chromosomal rearrangements and mutations. To determine the frequency 
and co-occurrence of mutations in T-cell acute lymphoblastic leukemia, we performed 
targeted re-sequencing of 115 genes across 155 diagnostic samples (45 adult and 110 
childhood cases). NOTCH1 and CDKN2A/B were mutated/deleted in more than half of the 
cases, while an additional 37 genes were mutated/deleted in 4 to 20% of cases. We 
identified the IL7R-JAK pathway to be mutated in 27.7% of cases, with JAK3 mutations being 
the most frequent event in this group. Copy number variations were also detected, including 
deletions of CREBBP or CTCF and duplication of MYB. FLT3 mutations were rare, but a 
novel extracellular mutation in FLT3 was detected and confirmed to be transforming. 
Furthermore, we identified complex patterns of pairwise associations, including a significant 
association between mutations in IL7R-JAK genes and epigenetic regulators (WT1, PRC2, 
PHF6). Our analyses showed that IL7R-JAK genetic lesions did not confer adverse 
prognosis in T-cell acute lymphoblastic leukemia cases enrolled in the UK ALL2003 trial. 
Overall, these results identify interconnections between the T-cell acute lymphoblastic 
leukemia genome and disease biology, and suggest a potential clinical application for JAK 
inhibitors in a significant proportion of T-cell acute lymphoblastic leukemia patients. 
 
Keywords: targeted sequencing, T-ALL, signaling, tyrosine kinase, epigenetic modulators 
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Introduction 
T-cell acute lymphoblastic leukemia (T-ALL) comprises a group of aggressive hematological 
tumors accounting for 10%-15% of pediatric and 25% of adult ALL cases, which are more 
frequent in males than females1-3. T-ALL development is a multi-step process in which 
different genetic lesions accumulate and alter the mechanisms controlling proliferation, 
survival, cell cycle and differentiation of T-cells. Loss of the CDKN2A (p16) locus and 
aberrant NOTCH1 signaling constitute the most predominant oncogenic lesions involved in 
the pathogenesis of T-ALL. Deletions of the CDKN2A locus in chromosome band 9p21 are 
present in up to 70% of T-ALL,4 while up to 60% carry NOTCH1 activating mutations.1 
NOTCH1 mutations lead to ligand independent cleavage and activation of the intracellular 
NOTCH1 part (ICN) and/or to stabilization of active protein.2 NOTCH1 is an essential protein 
for T-cell development and aberrant activation of NOTCH1 in T-ALL affects many different 
pathways including the cell cycle, NFκB and PI3K/AKT pathways. In addition, T-ALL cases 
harbor chromosomal rearrangements that result in aberrant expression of transcription factor 
genes, such as TLX1, TLX3, TAL1, LMO2, and HOXA.5-10 These chromosomal aberrations 
are often used to classify T-ALL into subclasses associated with expression of one of these 
transcription factors, which in many cases also resembles a specific block in differentiation.11 
 
The mutational landscape of T-ALL also includes somatic mutations of IL7R, JAK3, JAK1, 
PTEN, and NRAS signaling proteins.12-15 Activating mutations in JAK1, JAK3 or IL7R lead to 
activation of the JAK/STAT pathway, resulting in stimulation of the proliferation and survival 
pathways in the leukemia cells. Recent next generation sequencing studies identified further 
recurrent mutations in proteins involved in mRNA degradation and translation (CNOT3 and 
RPL10) and in proteins implicated in the regulation of chromatin structure, including histone 
demethylases (KDM6A/UTX), and members of the polycomb repressive complex 2 (PRC2: 
genes EZH2, SUZ12 and EED). 16-19 Sequencing studies have suggested that on average 10 
to 20 protein altering mutations can be detected in T-ALL cells,18-20 but their exact frequency 
and patterns of co-occurrence have not been investigated in detail in large T-ALL cohorts. 
 
Here, we used Haloplex targeted DNA capture followed by Illumina massive parallel 
sequencing to investigate the coding sequence of 115 recurrently mutated genes in a cohort 
of 155 T-ALL samples. Our results revealed that 40 genes had genetic alterations (combining 
sequence mutations with copy number variations) in more than 4% of cases. Our 
comprehensive sequence analysis identified mutations/copy number variations of the IL7R-
JAK signaling pathway members in 27.7% of T-ALL samples screened; an observation with 
therapeutic potential. Statistically significant pairwise associations were found between 
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different mutations, indicating the presence of functional interactions among different 
pathways in T-ALL pathogenesis. Of significance, we found a mutually exclusive relationship 
between IL7R-JAK mutations and the presence of TAL1/LMO2 rearrangements. We also 
identified positive correlations among IL7R-JAK mutations and mutations/deletions in PHF6 
and members of the PRC2 complex. Our findings begin to unravel the diversity of genetic 
lesions that are implicated in T-ALL development. 
Methods 
DNA samples 
T-ALL patient samples (n=155: 111 children, 44 adults) were collected from various 
institutions (Supplementary Table 1). Diagnosis of T-ALL was based on morphology, 
cytochemistry and immunophenotyping according to the World Health Organization criteria. 
Genomic DNA was isolated from bone marrow (either fixed or fresh bone marrow cells). 5,21,22 
To investigate the prognostic relevance of IL7R, JAK1 and JAK3 mutations, screening for 
mutations in these three genes by Sanger sequencing was performed in an independent 
cohort of 78 T-ALL patients. Those patients were all enrolled into the United Kingdom (UK)_ 
Children’s Cancer and Leukaemia Group (CCLG) ALL2003 trial.23 This study was approved 
byt the ethics committees of the institutes involved and informed consent was obtained. 
Samples and clinical data were stored in accordance with the declaration of Helsinki. 
Capture design 
The SureDesign software was used to design two slightly different Haloplex capture assays 
(Table 1). The total amplicon number for design A was 23127 with a region size of 472.006 
kbp and a predicted target coverage of >99%. For design B the total amplicon number was 
19694 with a region size of 418.373kbp and a predicted target coverage of >99%. For this 
study, 80 samples were processed with Design A and 75 samples with Design B. In both 
assays, the coding exons of selected genes (based on RefSeq, CCDS and VEGA 
databases) were targeted with an extra 10 bases upstream and downstream. Targeted 
regions comprised the coding sequence of genes that were either recently identified as 
recurrently mutated in ALL or other hematological malignancies (known driver genes) or 
were similar to known oncogenes (candidate driver genes) to be sequenced18,19,24,25. For 
statistical analyses we only considered the 115 genes that were sequenced in both Haloplex 
designs (Supplementary Table 2). Library preparation and sequencing was performed as 
described in the Supplementary material.  
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Data analyses 
In the NextGENe software (v2.2.1, Softgenetics, State College, PA, USA), we performed the 
following steps: (1) the fastQ output file was converted into a FASTA file to eliminate reads 
that were not “paired” and that did not meet the criteria of the default settings; (2) reads from 
the converted unique FASTA file were aligned to the reference genome (Human_v37.2). 
After alignment a *.pjt file was created and opened in the NextGENe Viewer; (3) a mutation 
report was created using the coordinates from the targeted enrichment kit as a *.bed file to 
enable calling of single nucleotide variants (SNVs) and small insertion/deletions (indels) in 
the regions of interest; (4) an expression report was created from which the mean, minimal 
and maximal coverage per target and targeted nucleotide was calculated. The coverage was 
defined as the average number of reads representing a given nucleotide in the reconstructed 
sequence. To interpret the data, additional custom-filtering criteria were imposed to minimize 
false-positive rates (Supplementary material). Polymorphisms annotated in dbSNP138 or 
1000 Genomes databases were excluded from the analyses. For variant calling we also 
required as a minimum a read depth of 20 and an allele frequency of at least 15%.  
In vitro cell experiments 
JAK3 wild type cDNA and mutants were generated by GenScript, and were cloned into the 
MSCV-GFP vector. Viral vector production, retroviral transduction and culture of Ba/F3 cells 
were performed as previously described.15 Western blot analyses were performed as 
described in the Supplementary material. 
Results 
Sequencing metrics and validation of the gene panel 
Next-generation sequencing studies have contributed significantly to our understanding of 
the genomic landscape of T-ALL. We recently profiled two cohorts of T-ALL using exome 
sequencing (67 cases)18 and RNA-sequencing (31 cases),24 while Zhang and colleagues 
profiled immature T-ALL cases (also known as early thymic or T-cell precursor T-ALL, ETP-
ALL) ETP-ALL using whole genome sequencing (12 cases)19 and targeted re-sequencing in 
94 childhood T-ALL cases. To determine the spectrum of mutations present in both adult and 
childhood T-ALL, we selected 155 T-ALL cases (44 adult/111 childhood) to be analyzed by 
targeted re-sequencing. These cases were derived from two different cohorts from France 
(n= 80) and UK (n= 75). Based on all available sequence data, we selected 115 genes that 
were recurrently mutated in ALL or other hematological malignancies. 
 
We used Haloplex enrichment to capture all exons of the selected genes, followed by 
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Illumina sequencing. Two slightly different designs were used to profile the two T-ALL 
cohorts, which yielded a total of 12.9 Gb of sequence, with capture efficiencies of 45 to 60%. 
The average coverage per sample was 209X. All genes were covered at >20X for at least 
95% of their coding regions (Table 1). After excluding sequencing/mapping errors and known 
polymorphisms, 685 single nucleotide variants (SNVs)-small insertions/deletions (indels) 
were identified in 103 genes as high-probability changes.  
 
In order to validate the accuracy of our Haloplex assay and bioinformatics analyses (to which 
we will refer as Haloplex analyses), we sequenced 158 variants across 33 genes using 
Sanger sequencing (Supplementary Table 3). We confirmed 137 of the 158 predicted SNVs 
and indels (86.7%). Furthermore, we also found that 124 additional SNVs and indels 
(although not validated here by Sanger sequencing), were already described and 
documented in the COSMIC database.26 To determine the sensitivity of Haloplex for 
detection of SNV and indels, we examined sequence mutations in CNOT3 (exon 5, n= 3/79) 
and RPL10 (exon 4, n= 2/79) and indels in IL7R (n= 12/155) and FLT3 (n= 1/155) genes, for 
which Sanger sequencing data were available. Haloplex identified all known point mutations 
in CNOT3 and RPL10, but failed to detect 6 of 12 IL7R indels and 1 of 1 FLT3-ITD 
(Supplementary Table 3). 
 
Data from Haloplex target enrichment can be also used to identify copy number variations 
(CNVs) at the captured loci.27 To this end, we normalized the coverage of all genes against 
the on-target mapped nucleotides across samples. First we looked at X-chromosome genes 
(MTMR8, KDM6A, PHF6, MAGEC3, RPL10 and USP9X). As shown in Figure 1A, all 
samples except one (TL91) showed read depths for X chromosome genes consistent with 
patient gender, with females showing a ~2 fold higher coverage than males. No copy number 
aberrations of MAGEC3 or USP9X genes were found. There was evidence for deletion of 
KDM6A (1 sample), MTMR8 (1 sample) and PHF6 (4 samples), with possible duplication of 
RPL10 (2 samples) or PHF6 (1 sample) genes (Figure 1A, Supplementary Table 3). 
 
To determine the accuracy of Haloplex data for the detection of CNVs, we examined CNVs 
at the MYB (n= 155), CDKN2A (n= 95) and PTPN2 (n= 80) loci for which FISH, MLPA or 
arrayCGH data were available. Overall, 64% (9/14) of cases with MYB duplication, 93% 
(69/74) of cases with CDKN2A deletion and 100% (6/6) of cases with PTPN2 deletion were 
identified by our Haloplex copy number analysis (Figure 1B, Supplementary Table 4). 
Haloplex data predicted four additional cases with MYB duplication that have a lower 
normalized coverage when compared with those samples with true MYB duplications. 
However, as they were not confirmed by any other method, we concluded that these were 
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false positive results. Together, our data indicated that Haloplex re-sequencing data can be 
used for the identification of SNVs and CNVs with high confidence, with deletions being 
easier to detect than duplications. The detection of larger indels is difficult, especially for 
longer insertions. 
Landscape of genetic alterations in T-ALL  
In total, 153 of the 155 patient samples (98.7%) harbored at least one sequence 
mutation/copy number change, with a median number of 5 (1–65) genetic lesions per 
sample. Known T-ALL tumor suppressor genes such as CDKN2A/B, PHF6, PTEN and 
PTPN2 were frequently identified as common targets of gene deletions. From the 115 genes 
analyzed, 40 genes showed genetic alterations (SNV, indel or CNV) in more than 4% of 
cases (Figure 2). Only NOTCH1, CDKN2A and CDKN2B aberrations were found in more 
than 50% of cases. Mutation frequencies of PHF6 (19.4%), FBXW7 (17.4%), WT1 (14.8%), 
PTEN (12.3%), BCL11B (12.3%) and PTPN2 (7.7%) were in the range of previously reported 
frequencies.2 Our data confirmed that JAK3 was frequently mutated in T-ALL (16.1%).19 
Other recently identified mutations were also found including CREBBP (7.7%),28 CNOT3 
(5.2%)18 and RPL10 (5.2%).18 In contrast to AML, FLT3 mutations were rare among the T-
ALL cases, although we identified one new mutation in the extracellular domain of FLT3 
(S471C), which was confirmed to be a transforming mutation (Supplementary Figure 1). 
 
Genes with identified genomic lesions were grouped into functional pathways linked to T-ALL 
pathogenesis (Supplementary Table 2). The most frequently affected pathway was 
transcriptional regulation, with mutations observed in as many as 81.9% of cases, followed 
by genes associated with cell cycle regulation (74.2%), chromatin modification (38.1%), 
genes encoding kinases (29.7%), phosphatases (26.5%) and DNA repair pathways (18.7%).  
 
The mean number and spectrum of some of the identified genetic lesions closely correlated 
with patient age and T-ALL subtype. Alterations in PTPN2 (p=0.005; 18.2% vs. 3.6%), MYB 
(p=0.008; 22.7% vs. 6.3%) and CREBBP (p=0.039; 15.9% vs. 4.5%) were more prevalent 
among adult cases. In contrast, EZH2 (p=0.006, 13.5%) and RPL10 (p=0.106, 7.2%) 
aberrations were exclusively found in children, although the trend did not reach significance 
for RPL10.  
 
We also found new and previously reported correlations between genetic lesions and T-ALL 
subgroups. Immature T-ALL cases had a lower incidence of CDKN2A (p<0.001, 13.3% vs. 
81.9%) and CDKN2B (p<0.001, 13.3% vs. 66.4%) deletions,19 while the incidence of 
mutations in JAK3 (p=0.001, 53.3% vs. 12.9%)19, JAKMIP2 (p=0.010, 26.7% vs. 4.3%), 
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RUNX1 (p=0.020, 20% vs. 2.6%)19 and IL7R (p=0.043, 26.7% vs. 7.8%)19 was significantly 
higher in those cases. Aberrations of PHF6 (p=0.006, 53.8% vs. 16.8%),29 PTPN2 (p=0.018, 
30.8% vs. 6.5%),22 and CDKN2B (p=0.014, 92.3% vs. 55.1%) were more frequently found 
among TLX1 positive cases. TLX3 positive cases had significantly more lesions in CDKN2A 
(p=0.001, 92.9% vs. 68.8%), CDKN2B (p=0.001, 85.7% vs. 52%), DNM2 (p=0.006, 28.6% 
vs. 8%), WT1 (p<0.001, 42.9% vs. 8.8%)30 and JAK1 mutations (p=0.001, 17.9% vs. 0.8%). 
PHF6 (p=0.005, 7.4% vs. 26%),29 JAK3 (p=0.002, 3.7% vs. 23%) DNM2 (p<0.001, 18%), 
PTPN2 (p=0.009, 12%) and WT1 (p=0.001, 1.9% vs. 22%) lesions were underrepresented in 
TAL1/LMO2 positive patients (Figure 3). 
The IL7R-JAK axis is an important oncogenic pathway in T-ALL 
The IL7R-JAK signaling cascade is an essential signaling pathway in hematopoiesis, and 
somatic mutations in IL7R, JAK1, JAK3 and STAT5 have been reported previously in T-
ALL.12,15,18,31 However, the exact frequency of mutations for all members of the signaling 
pathway is unclear. In our series, sequence mutations/copy number variations of the IL7R, 
JAK1, JAK3 and STAT5 genes were found in 27.7% of cases, confirming that this signaling 
pathway is an important oncogenic axis in T-ALL (Figure 4A). Incidences of cases with 
genetic lesions of IL7R, JAK1, JAK3 and STAT5 genes were 9.7%, 4.5%, 16.1% and 4.5%, 
respectively. We found that 5.8% of cases carried combinations of these mutations 
(Supplementary table 2).  
 
We identified JAK3 as the most common targeted member of the pathway (16.1% of T-ALL 
cases). Most mutations were located within the pseudokinase domain, which has a 
regulatory function on kinase activity (Figure 4A). The M511I mutation was the most 
frequent. In 34.7% of JAK3 mutant cases the M511I mutation was detected together with a 
second mutation of JAK3 (Figure 4B). Seven patients had mutations/duplications of IL7R 
(n=2), JAK1 (n=3) or STAT5 (n=2) in addition to a JAK3 mutation. 
 
The majority of JAK3 mutations identified in T-ALL have been confirmed as activating 
mutations,15 but the transforming capacity of four JAK3 mutations identified in this study 
(Q283H, V678L, Q865E and E958K) was not studied previously. We expressed these 
mutants in Ba/F3 cells and confirmed that JAK3 V678L and Q865E were capable of 
transforming the cells to IL3 independent growth (Figure 4C). The JAK3 Q283H and Q865E 
mutants were not transforming (Figure 4C), suggesting that these may be passenger 
mutations. In summary, our results show that the IL7R-JAK signaling pathway is frequently 
mutated in T-ALL, with JAK3 being the most frequently altered gene (14.9% of T-ALL cases 
harbor transforming JAK3 mutations). 
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Mutations of the IL7R-JAK axis and epigenetic modulators are associated in T-ALL 
Having observed that the components of the IL7R-JAK axis were frequently mutated in T-
ALL, we analyzed the possible associations between these mutations and the different T-ALL 
subgroups (Table 2). The cases having IL7R-JAK mutations were more frequently found 
among TLX3+ cases (31% vs. 13.5, p=0.013), immature T-ALL cases (25% vs. 5.5%, 
p=0.002),19 or HOXA+ cases (20.9% vs. 5.4%, p=0.006), but underrepresented among 
TAL1/LMO2 positive cases (p=0.001, 14% vs. 43.2%). Of importance, we observed that 
mutations of IL7R-JAK were positively associated with mutations in epigenetic factors 
(p=0.001, 42.4% vs. 18.8%). More detailed analyses revealed specific associations between 
mutations in IL7R-JAK and PHF6 (p=0.002, 34.9% vs. 13.4%), WT1 (p=0.001, 30.2% vs. 
8.9%), and members of the PRC2 complex (EZH2, SUZ12 and EED) (p=0.033, 27.9% vs. 
13.4%) (Table 2). If we take into account the two JAK3 mutations (Q283H and Q865E) that 
lack transforming potential, the significance of these associations is not altered 
(Supplementary material). Together, these results indicate that functional interactions are 
present between the IL7R-JAK signaling pathway and epigenetic modifiers (WT1, PHF6, 
PRC2). 
Co-occurring mutations and analysis of clonality in cases with IL7R-JAK mutations 
Clonal evolution has been documented in a range of hematological malignancies.32 The 
proportion of sequencing reads reporting a given mutation can be used to identify whether 
mutations are present in the major clone or a subclone at the time of diagnosis.  
 
Overall, we did not observe any specific genes that were more frequently mutated in 
subclones. As we had detected a high frequency of JAK3 mutations, we analyzed the 23 
cases with JAK3 mutations in more detail (Figure 5). Of these cases, 82.6% showed the 
presence of the JAK3 mutation in more than 35% of the cells, indicating that JAK3 mutations 
occur predominantly in the major clone at diagnosis. One of these cases carried a JAK3 
M511I mutation at an allele frequency of 96.4%. As there were no copy number variations 
and the allele frequency for the SNPs present in that genomic region was around 100%, we 
conclude that copy number neutral loss of heterozygosity was responsible for this 
homozygous JAK3 mutation. In cases with two JAK3 mutations or with JAK3 and JAK1 
mutations together, one JAK3 mutation was typically present in the major clone (>40% VAF 
in 9 out of 12 cases), with a minor clone having the second mutation (or both mutations). 
These data confirm that a single JAK3 mutation can contribute to leukemia development, 
while the acquisition of an additional JAK3 or JAK1 mutation is likely to be of benefit for 
driving the growth of subclones during disease progression. 
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Mutations of IL7R, JAK3 and JAK1 genes do not have an adverse prognostic impact 
To gain insight into the clinical relevance of IL7R, JAK3 and JAK1 mutations, we analyzed 
their prognostic significance in a cohort of 78 T-ALL cases treated on the UKALL2003 
protocol.23 Sanger sequencing analyses revealed that 10 of the 78 cases (12.8%) carried 
mutations in IL7R-JAK genes. The seven males and three females were aged 2 to 22 years 
old and 7 were classified as NCI high risk. All patients achieved complete remission within 28 
days but 4/8 were minimal residual disease (MRD) positive at this time point. Eight of the 10 
patients (80%) remain in first complete remission 3.7-6.9 years from diagnosis. The other two 
patients (both carrying IL7R indels) relapsed. One male who presented before his second 
birthday and with a very high white cell count (497x109/L) experienced an isolated central 
nervous system relapse after 9 months and subsequently died. The second patient, a 13-
year-old male, experienced an isolated bone marrow relapse after 18 months, but remains 
alive 3.3 years after an HLA-matched unrelated donor transplant despite failing induction 
after relapse. In conclusion, this cohort of T-ALL patients fared quite well, and there is no 
evidence that IL7R-JAK mutations are associated with a poor prognosis. 
Discussion 
We have performed targeted sequencing of a large cohort of T-ALL cases, coupled with a 
comprehensive study of their genetic background, in order to elucidate molecular lesions and 
their co-occurrence in patient samples. We used Haloplex enrichment to sequence the entire 
coding regions of 115 genes (known T-ALL driver genes or candidate driver genes). We 
showed that Haloplex sequencing for the detection of SNVs is highly specific and sensitive. 
Deletions of entire genes were also detected with a high degree of accuracy. In contrast, the 
detection of gene duplications and indels, such as MYB duplications and insertions into the 
IL7R and FLT3 genes was less reliable, leading to false positive detection of duplications and 
false negative detection of indels. Similar findings were recently shown for targeted re-
sequencing in acute myeloid leukemia, and it was shown that increased coverage could 
improve the identification of copy number alterations in Haloplex assays.27 Haloplex analyses 
should not be preferred over aCGH or MLPA techniques for detection of copy number 
variations, especially for the detection of duplications.  
 
Visual inspection of the reads for IL7R and FLT3 identified mutant alleles with indels, which 
had been missed by the analysis software. However, in most cases the mutant reads were 
missing, suggesting that the mutant exons had not been adequately captured during the 
target enrichment step. These observations highlight the need for further refinements to the 
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alignment algorithms and the capture design for cancer samples, which will greatly increase 
the ability to detect large indels such as those present in IL7R and FLT3.  
 
Once the Haloplex method was successfully validated, we used this approach to 
characterize the mutational profile of a cohort of 155 T-ALL cases. Targeted re-sequencing 
was performed in absence of germline/remission matched DNA and this should be 
considered. However, the fact that we identified known gene mutations/copy number 
variations at the same frequencies in our T-ALL cohort as reported in the literature, confirms 
both the validity of our approach and our cohort. Similar to observations in other tumors, only 
a few genes (NOTCH1, CDKN2A/B) were mutated or deleted in >50% of the T-ALL cases, 
while a large number were mutated in <20% of the cases. These observations corroborate 
the complexity and variation of events underlying T-ALL malignant transformation.  
 
We observed that the IL7R-JAK signaling pathway was targeted in 27.7% of T-ALL. These 
findings have potential therapeutic implications, as JAK kinase inhibitors are known to target 
these alterations. 15,33-38 JAK3 is the most frequently mutated gene (16.1% of T-ALL cases) 
within the IL7R-JAK signaling pathway. Based on the results described in this manuscript 
and our previously published work,15 the transforming capacities of a total of 16 JAK3 
mutants have been tested using the Ba/F3 in vitro cell system. Six of these 16 JAK3 mutants 
(R272H, Q283H, R403H, Q865E, R925S and E1106G) lacked transforming potential, 
illustrating that results from sequencing need to be confirmed by functional assays to 
distinguish driver mutations from passenger mutations. If we exclude the JAK3 mutations 
that lack transforming potential, then the frequency of cases with JAK3 mutations in our 
series is 14.9% (instead 16.1%). 
 
Some T-ALL cases harbored two transforming JAK3 mutations, which suggests that those T-
ALL cells that are dependent on a JAK3 mutation may gain proliferative advantage by 
mutating the second JAK3 allele. In line with this hypothesis, our clonality analysis of JAK3 
mutated cases showed that in those with two JAK3 mutations or a JAK3 and JAK1 mutation 
together, one JAK3 mutation was typically present in the major clone, with the second 
mutation found in a lower percentage of the cells, most likely representing a minor clone.  
 
We also investigated the prognostic impact of mutations of IL7R, JAK1 and JAK3, using data 
from the UKALL2003 trial, in particular because these mutations occur more frequently in 
immature T-ALL, a subgroup of T-ALL initially associated with a poor outcome in some 
studies.39 
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Despite the small subset of IL7R, JAK1 or JAK3 mutant T-ALL patients (n=10) in this cohort, 
it appeared that in general these patients fared well. It should be noted that the outcome of 
immature T-ALL patients has improved since initial reports of this subtype, and that more 
recent data from UKALL2003 and COG AALL0434 suggest immature T-ALL patients may 
not have worse outcome with intensified therapy.23,40  In fact, seven of the 10 patients with 
mutations within the IL7R-JAK pathway received very intensive chemotherapy based on risk 
stratification. Our data provide no evidence that IL7R, JAK1 and JAK3 mutations are a 
consistent marker of poor prognosis. Nevertheless, it might be that immature T-ALL cases 
harboring IL7R-JAK mutations would benefit from the use of JAK inhibitors in T-ALL trials, 
since it might reduce the toxic side effects from high-dose chemotherapy treatments. The 
efficacy of ruxolitinib (JAK1/2 inhibitor) was recently demonstrated in murine xenograft 
models of immature T-ALL.41 Of interest, both JAK/STAT pathway activation and ruxolitinib 
efficacy were independent of the presence of JAK/STAT pathway mutations, raising the 
possibility that the therapeutic potential of ruxolitinib in T-ALL extends beyond those cases 
with JAK mutations.41 Further studies are warranted to clarify this issue. 
 
Importantly, we have found statistically significant associations between gene mutations and 
signaling pathway-groups or T-ALL patient characteristics. These include previously 
described associations between immature T-ALL and JAK3 mutations19, and between TLX1 
positive cases and PHF6 mutations/deletions.29 Our current study points out that mutations 
in PHF6, WT1 and PRC2 complex members are particularly prevalent in T-ALL cases 
harboring mutations of the IL7R-JAK signaling pathway. We speculate that such epigenetic 
mutations could result in chromatin changes that will affect the accessibility of STAT5 target 
genes for transcription, cooperating in this way with the activation of the IL7R-JAK-STAT 
signaling pathway. Functional studies are needed to understand the underlying mechanism 
of this association. 
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Table 1. Targeted sequencing summary of 155 T-ALL samples 
 
 
Design A  
(n=80 T-ALL cases) 
Design B  
(n=75 T-ALL samples) 
Design information 
    
Number of genes in design 149 141 
Region size of the design (kbp) 472.006 418.373 
Total amplicons in design 23127 19694 
Minimum sequencing required (Mbp) 247.7 229.35 
Sequence information 
    
Reads passing filtration (Gb) 8.7 (3.0 - 25.0) 4.2 (1.4 - 14.5) 
Reads mapped (%) 98.1 (90.4 - 99.1) 79.6 (41.4 - 96.2) 
Capture efficiency (%)* 60.8 (55 - 66.3) 45.5 (23.2 - 56.5) 
Mean depth 2312 (733 - 6580) 959 (199 - 3586) 
≥ 10x coverage (%)† 97.9 (94.9 - 99.0) 97.0 (91.2 - 98.6) 
≥ 20x coverage (%)† 97.1 (92.6 - 98.8) 95.6 (85.6 - 98.2) 
≥ 50x coverage (%)† 94.9 (87.0 - 98.0) 91.8 (73.1 - 97.2) 
≥ 100x coverage (%)† 91.9 (79.7 - 94.3) 85.3 (57.5 - 96.2) 
≥ 200x coverage (%)† 86.6 (66.7 - 94.3) 73.5 (31.1 - 94.4) 
 
Data are presented median (0.25~0.75quartile).  
*Capture Efficiency (%), the ratio of the read number that mapped to the targeted region to the 
total read number. 
†≥ 10x, 20x, 50x, 100x, 200x coverage (%), the ratio of target regions covered 10, 20, 50, 100 or 
200x to the total number of target regions. 
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Table 2. Overall clinical, immunophenotypic and molecular cytogenetic characteristics of T-ALL 
patients with mutations in the IL7R-JAK signaling pathway 
 
 
  IL7R-JAK signaling pathway 
  
Wt (n=112) Mut (n=43) P 
Type of 
Association 
  
Clinical               
Gender      0.586   
     Male   83 (74.1%) 30 (69.8%)     
     Female  29 (25.9%) 13 (30.2%)    
Median age (range) 11 (1-63) 12 (2-66) 0.767†   
T-ALL clusters Wt Mut P   
HOXA+ (n=15)  6 (5.4%) 9 (20.9%) 0.006* Positive 
TLX1+ (n=13)   10 (11.2%) 3 (9.7%) 1.000*   
TLX3+ (n=28)  15 (13.5%) 13 (31%) 0.013 Positive 
TAL1/LMO2+ (n=54)   48 (43.2%) 6 (14%) 0.001 Negative 
Immature T-ALL+ (n=14) 4 (4.4%) 10 (25%) 0.001* Positive 
Del9p21 status Wt Mut P   
Wild-type  27 (24.1%) 13 (30.2%)    
Mutant   85 (75.9%) 30 (69.8%) 0.435   
PHF6 status Wt Mut P   
Wild-type  97 (86.6%) 28 (65.1%)    
Mutant   15 (13.4%) 15 (34.9%) 0.002 Positive 
PRC2 status Wt Mut P   
Wild-type  97 (86.6%) 31 (72.1%)    
Mutant   15 (13.4%) 12 (27.9%) 0.033 Positive 
WT1 status   Wt Mut P   
Wild-type  102 (91.1%) 30 (69.8%)    
Mutant   10 (8.9%) 13 (30.2%) 0.001 Positive 
 
Wt: wild-type; Mut: mutant; P: P value. Median age indicated in years. 
Significant P values are indicated in bold; all P values were calculated by using Pearson's χ2 test, 
unless indicated otherwise: *Fisher's exact test; †Mann-Whitney-U test.  
The HOXA+, TLX1+ and TLX3+ and TAL1/LMO2+ groups were based on the presence of 
HOXA, TLX1, TLX3, TAL1 or LMO2 rearrangements or by having a HOXA, TLX1, TLX3 or 
TAL1/LMO2 expression signature. The immature T-ALL group was defined 
immunophenotypically or based on gene expression cluster analysis. 
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Figure Legends 
 
Figure 1. Haloplex target enrichment analyses can be used to identify copy number 
variations. For MAGEC3, KDM6A, MYB and PTPN2 genes, the normalized coverage 
against the on-target mapped nucleotides is plotted for all patients on an arbitrary linear 
scale. In order to find out real copy number variations, for each gene we calculated the first 
quartile (Q1), third quartile (Q3) and the interquartile range (IQR= Q1 – Q3) from the 
normalized coverage values. Samples having a normalized coverage for a particular gene 
greater than Q3+1.5*IQR were considered to have a duplication/amplification in that gene. 
Conversely, samples having a normalized coverage less than Q1-1.5*IQR, were considered 
to carry a deletion. The calculated values for each gene are represented in the graphs as 
dotted lines. For X-chromosome genes, we did those calculations taking along only male or 
female samples. (A) Read depths for MAGEC3 are consistent with patient gender (except 
case number TL91), with females showing a ~2 fold higher coverage than males. While no 
copy number variations were found in MAGEC3, there was evidence for deletion of KDM6A 
in case number 4139. (B) By using Haloplex we were able to confirm the presence of PTPN2 
deletions in all (6/6) PTPN2 positive cases (shown as blue dots in the graphs). MYB 
duplications were confirmed in 64% (9/14) of MYB positive cases (orange dots). Haloplex 
analyses predicted four additional cases carrying MYB duplication (pink dots), which were 
false positive results. 
 
Figure 2. Overview of the genetic lesions identified in the most frequently mutated 
genes in T-ALL. (A) Single nucleotide variants, indels and copy number variations are 
shown for the 40 genes we found mutated in more than 4% of the cases in our series. Each 
type of mutation is indicated by different color. Age, gender and T-ALL characteristics are 
also shown for each patient (bottom table). (B) Spectrum of genetic lesions in IL7R-JAK 
signaling members (IL7R, JAK3, JAK1 and STAT5 genes), PHF6, PRC2 complex members 
(SUZ12, EZH2 and EED) and WT1. The cases having PHF6, PRC2 and WT1 mutations 
were more frequently found among IL7R-JAK positive cases. 
 
Figure 3. The spectrum of some of the identified genetic lesions closely correlated 
with patient characteristics and T-ALL subtypes. Associations between the most 
frequently mutated genes (top 40 genes, ranked from the most frequently targeted gene) and 
patient characteristics-T-ALL subtypes are shown. Associations with p-values lower than 
0.05, 0.01 and 0.001 are indicated with circles of different sizes. Positive associations are 
shown in orange color, negative associations are shown in blue color. Associations that 
could not be considered as positive or negative are shown in gray color. A = adult group, P = 
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pediatric group, F = female group. 
 
Figure 4. Overview of the identified mutations in the IL7R-JAK signaling pathway 
members. (A) Schematic view of the IL7R, JAK3, JAK1, STAT5A and STAT5B proteins and 
their main protein domains. The mutations found on each of those proteins are shown. (B) 
The variant allele frequencies for JAK3 mutations are shown in the graph. In eight out of the 
23 cases carrying JAK3 mutations (case numbers indicated with asterisks), the M511I 
mutation was detected together with a second mutation of JAK3. (C) Proliferation curve of 
Ba/F3 cells expressing various JAK3 mutants or the empty vector, in the absence of 
cytokines. Mutations that did not stimulate proliferation more than the empty vector were 
considered as not transforming mutants. (D) Western blot analysis of whole cell lysates of 
Ba/F3 cells transformed by the JAK3 mutants V678L and E958K, or empty vector. A protein 
lysate of Ba/F3 cells transformed by the JAK3 M511I mutant (previously described as 
transforming) was included as a positive control.  Phosphorylation of JAK1 and JAK3 was 
detected for all JAK3 mutants. JAK3 protein expression was detected with a human specific 
antibody, not recognizing the endogenous Jak3 expression. The transforming JAK3 mutants 
were able to phosphorylate STAT5. 
 
Figure 5. JAK3 mutations occur predominantly in the major clone at diagnosis. Variant 
allele fractions of the mutated genes identified in the 23 cases with JAK3 mutations. For 
clarity reasons, only those genes mutated in more than 4% of T-ALL cases are shown. JAK3 
mutations are predominantly present in the major clone when two JAK3 mutations or JAK3 
and JAK1 mutations occur together, while a minor clone has the second mutation.  
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1.	  Supplementary	  Methods	  
DNA	  samples	  
T-ALL patients (n=155: 111 children, 44 adults) were collected from various 
institutions. Samples had been previously characterized for oncogene expression 
and classified into oncogenic subgroups according to combined FISH (fluorescence 
in situ hybridization) analyses, immunophenotypic data and oncogene expression. 
Copy number changes of CDKN2A (n=95), MYB (n=115) and PTPN2 (n=80) had 
been previously identified by FISH, MLPA (Multiplex Ligation-dependent Probe 
Amplification) or arrayCGH. The HOXA+, TLX1+ and TLX3+ and TAL1/LMO2+ 
groups were based on the presence of HOXA, TLX1, TLX3, TAL1 or LMO2 
rearrangements or by having a HOXA, TLX1, TLX3 or TAL1/LMO2 expression 
signature. The immature T-ALL group (also known as early thymic or T-cell precursor 
T-ALL) was defined immunophenotypically or based on gene expression cluster 
analysis. 
Haloplex	  library	  preparation	  and	  sequencing	  
Enrichment of the region of interest was performed using the Haloplex Target 
Enrichment System-Fast Protocol. Briefly, 200 ng of DNA per sample was aliquoted 
into 8 digestion reactions, each containing 2 restriction enzymes. DNA from the 8 
reactions was then pooled and hybridized to Haloplex probes, allowing for 
purification using magnetic beads. Purified fragments were ligated, amplified and 
barcoded through 19 cycles of PCR and samples were sequenced on a HiSeq2000 
instrument using a 100 bp paired-end protocol. The HiSeq Paired End Cluster 
Generation Kit was used to generate the clusters and the TruSeq SBS Kit v3 was 
used for sequencing. Image analysis and base calling was performed using the 
Illumina RTA software version 1.13.48.  
The additional custom filtering criteria refers to the fact that we excluded five variants 
that were identified in nearly all samples analyzed. Since those variants were not 
found in dbSNP138, 1000 Genomes or the COSMIC databases, we believe these 
are false positives of data analysis. These are the variants that have been excluded 
from the analyses: 
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Position Gene Nucleotide change Amino acid change 
6037058	   PMS2	   delAA	   	  	  
103141302	   RELN	   C>CT	   2853G>GS	  
90645514	   IDH2	   G>GT	   37R>SR	  
29508805	   NF1	   T>GT	   Splice	  
103629804	   RELN	   insGCCGCC	   Splice	  
Validation	  of	  identified	  genomic	  lesions	  
We sequenced 158 selected variants (Supplementary Table 3) using Sanger 
sequencing. Analysis of the chromatograms from Sanger sequencing was performed 
using CLC Main Workbench 6 (CLC Bio).  
Western	  blot	  analyses	  
Cells were lysed in cold lysis buffer containing 5 mM Na3VO4 and protease inhibitors 
(Complete tablets, Roche). The proteins were separated on NuPAGE NOVEX Bis-
Tris 4%–12% gels (Invitrogen) and transferred to PVDF membranes. Subsequent 
Western blot analysis was performed using primary antibodies directed against JAK1 
(Millipore), JAK3, phospho-STAT5, (Cell Signaling), phospho-JAK1, STAT5 (Santa 
Cruz Biotech.) and β-actin (Sigma). Anti-phospho-JAK1 antibody was used to detect 
both phosphorylated JAK1 and JAK3. Western blot detection was performed using 
secondary antibodies conjugated with horseradish peroxidase (GE Healthcare) and 
western blot lightning plus-ECL (PerkinElmer).  
Statistical	  analyses	  
Statistical analyses were carried out using SPSSstatistics v21. Pearson’s X2 Fisher’s 
exact tests were performed to test significance levels for nominal data distributions, 
whereas the Mann-Whitney U test was used for continuous data. 
Validation	  of	  the	  newly	  identified	  FLT3	  S471C	  mutation	  
The FLT3-S471C variant was generated by GenScript, and was cloned into the 
MSCV-GFP vector. Viral vector production, retroviral transduction and culture of 
Ba/F3 cells were performed as previously described.1 Ba/F3 cells expressing the 
FLT3-ITD (W51 mutation, Kelly et al.2) and FLT3-D835Y were previously described.3 
Western blot analyses were performed as indicated above using antibodies directed 
against FLT3, STAT5 (Santa Cruz Biotech.), anti-phosphoFLT3 (Tyr591), phospho-
STAT5 (Cell Signaling) and β-actin (Sigma). Immunoprecipitations was not 
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performed prior western blot analyses. In order to test the sensitivity of the FLT3-
S471C variant to FLT3 inhibition, Ba/F3 cells expressing FLT3-S471C, FLT3-ITD and 
FLT3-D835Y were treated with 1000nM of the inhibitor AC220 for 30 minutes, and 
analyzed by western blotting. For dose-response experiments we used 8 different 
AC220 concentrations (50, 100, 200, 400, 800, 1600, 3200 and 6400 nM) each in 
triplicate with DMSO as a negative control. The number of viable cells was counted 
after the treatment 24h with ATP-lite 1step reagent (PerkinElmer). Luminescence 
was measured with the multilabel plate readers Envision and Victor X4 
(PerkinElmer). IC50 values were calculated with GraphPad Prism. 
  
	   5	  
2.	  Supplementary	  Results	  
In our association analyses, the putative JAK3 passenger mutants (JAK3 
Q283H and Q865E mutants that were unable to transform Ba/F3 cells) were 
initially considered as mutants. We performed the same association analyses 
excluding those JAK3 passenger mutant cases (scored now as wild type).  
 
Then, the frequency of cases with IL7R-JAK mutations in our series is 26.5% 
(instead 27.7%). All the associations we found with the IL7R-JAK positive 
cases remained significant as shown in the table below. 
 
  
IL7R-JAK signaling pathway 
  
Wt (n=114) Mut (n=41) P 
Type of 
Association 
  Clinical               
Gender 
     
0.539   
     Male   85 (74.6%) 28 (68.3%)     
     Female 
 
29 (25.4%) 13 (31.7%) 
 
  
Median age (range) 11 (1-63) 12 (2-66) 0.849†   
T-ALL clusters Wt Mut P   
HOXA+ (n=15) 
 
6 (5.3%) 9 (22%) 0.004‡ Positive 
TLX1+ (n=13)   10 (11.0%) 3 (10.3%) 1.000‡   
TLX3+ (n=28) 
 
15 (13.3%) 13 (32.5%) 0.007 Positive 
TAL1/LMO2+ (n=54)   49 (43.4%) 5 (12.2%) <0.001 Negative 
Immature+ (n=14) 4 (4.3%) 10 (25.6%) 0.001‡ Positive 
Del9p21 status Wt Mut P   
Wild-type 
 
28 (24.6%) 12 (29.3%) 
 
  
Mutant   86 (75.4%) 29 (70.7%) 0.541   
PHF6 status Wt Mut P   
Wild-type 
 
99 (86.8%) 26 (63.4%) 
 
  
Mutant   15 (13.2%) 15 (36.6%) 0.001 Positive 
PRC2 status Wt Mut P   
Wild-type 
 
99 (86.8%) 29 (70.7%) 
 
  
Mutant   15 (13.2%) 12 (29.3%) 0.020 Positive 
WT1 status   Wt Mut P   
Wild-type 
 
104 (91.2%) 30 (68.3%) 
 
  
Mutant   10 (8.8%) 13 (31.7%) 0.001 Positive 
 
 
  
	   6	  
3.	  Supplementary	  Figures	  
Figure S1. The newly identified mutation in the extracellular domain of FLT3 
(S471C) is a transforming mutation 
	  	  	  
Sanger sequence
Consensus mutated
sequence
Reference sequence TCAGACAAGTCTCCC
S D K S P
TCAGACAAGTNTCCC
S D K C P
A B
C
D
pFLT3 pSTAT5
Ba
/F3
 FL
T3
 IT
D D
MS
O
Ba
/F3
 FL
T3
 IT
D A
C2
20
 
Ba
/F3
 FL
T3
 S4
71
C D
MS
O
Ba
/F3
 FL
T3
 S4
71
C  
AC
22
0 
Ba
/F3
 FL
T3
 D8
35
Y  
DM
SO
Ba
/F3
 FL
T3
 D8
35
Y A
C2
20
 
FLT3 STAT5
*
*
*
IC50: 5921 nM
IC50: 3.048 nM
IC50: 1635 nM
IC50: 1.802 nM
Ba/F3 FLT3 ITD IL3
Ba/F3  FLT3 ITD no IL3
Ba/F3 FLT3 S471C IL3
Ba/F3  FLT3 S471 no IL3
Log [AC220]
Ba
/F3
 FL
T3
 IT
D D
MS
O
Ba
/F3
 FL
T3
 IT
D A
C2
20
 
Ba
/F3
 FL
T3
 S4
71
C D
MS
O
Ba
/F3
 FL
T3
 S4
71
C  
AC
22
0 
Ba
/F3
 FL
T3
 D8
35
Y  
DM
SO
Ba
/F3
 FL
T3
 D8
35
Y A
C2
20
 
b-actin b-actin
	   7	  
Figure S1. The newly identified mutation in the extracellular domain of FLT3 
(S471C) is a transforming mutation. (A) Sanger sequencing confirmation of the 
FLT3-S471C variant (B) Proliferation curve of Ba/F3 cells expressing FLT3-ITD, 
FLT3-D835Y and FLT3-S471C variants. Cells expressing FLT3-S471C were able to 
grow in the absence of IL3. Ba/F3 cells expressing FLT3-ITD, FLT3-D835Y or Ba/F3 
wild type supplemented with IL-3 were used as a positive control. Cells expressing 
Ba/F3 cells wild type without IL-3 were used as a negative control. (C) Western 
blotting showing the phosphorylation and expression of signaling proteins. The 
expression in Ba/F3 cells of the variant FLT3-S471C resulted in constitutive 
phosphorylation of FLT3 and STAT5. The level of phosphorylation was lower 
compared to Ba/F3 cells carrying FLT3-ITD and FLT3-D835Y that correlates with the 
slower proliferation detected also in comparison with cells expressing FLT3-ITD or 
FLT3-D835Y. The phosphorylation of FLT3 was reduced for all the Ba/F3 upon 
treatment with AC220. However, the phosphorylation of STAT5 could be detected 
after the treatment with AC220 for the cells carrying the S471S and the D835Y 
mutations. (D) We calculated the IC50 values for the AC220 inhibitor treating the 
cells with FLT3-S741C or FLT3-ITD with increasing concentrations of the inhibitor 
and measuring the proliferation after 24 hours of inhibition. Both cell lines were highly 
sensitive to the treatment with AC220 with IC50 values lower than 5 nM. 
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